Cite
MLA Citation
Andrew Davies et al.. “Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial.” Lancet oncology, vol. 20, no. 5, 2019, pp. 649–662. http://access.bl.uk/ark:/81055/vdc_100081476495.0x000012